	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	377	832	1,008	1,319	1,339	1,049	1,195	2,269
Cost of Operating Revenue	154	344	447	589	616	487	430	850
Gross Profit	223	488	561	729	723	562	765	1,419
Gross Margin	59.1	58.7	55.7	55.3	54.0	53.6	64.0	62.5
Total Operating Expenses	214	470	599	778	820	695	867	2,029
Operating Profit	163	361	409	541	519	355	328	240
Operating Margin	43.2	43.4	40.6	41.0	38.7	33.8	27.5	10.6
Financing Income/(Expense) - Net	-5	-12	1	10	38	48	1	-37
Profit before Taxes	158	405	468	668	560	406	344	207
Income Taxes	49	88	105	214	148	105	79	57
Profit after Tax	109	317	362	454	411	300	268	179
PAT Margin	29.0	38.1	35.9	34.4	30.7	28.6	22.4	7.9
EPS - Basic - ex Extraordinary Items	4.29	12.45	14.23	17.83	16.16	11.80	10.52	4.69
EPS - Diluted - ex Extraordinary Items	4.29	12.45	14.23	17.83	16.16	11.80	10.47	4.68
EBIT	163	361	409	541	519	355	328	240
EBITDA	174	385	440	580	567	409	406	427
EBITDA Margin	46.2	46.3	43.7	44.0	42.3	39.0	33.9	18.8

Balance Sheet

Abridged

Understanding Balance Sheet

Cohance Lifesciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	390	392	565	1,128	1,011	1,263	853	1,796
Long-Term Investments	0	0	0	-	-	9	0	295
Property Plant & Equipment - Net	379	456	535	562	766	787	1,250	2,163
Total Non-Current Assets	393	781	910	702	955	991	2,178	3,933
Total Assets	783	1,173	1,474	1,830	1,966	2,254	3,032	5,730
Total Current Liabilities	158	200	220	210	159	107	365	646
Long Term Debt	-	92	36	29	5	21	176	256
Total Non-Current Liabilities	35	128	74	92	72	97	826	1,050
Total Liabilities	193	328	294	302	231	203	1,191	1,696
Total Shareholders' Equity	590	845	1,181	1,527	1,735	2,051	1,697	3,911
Minority Interest	-	-	-	-	-	-	144	123
Total Equity	590	845	1,181	1,527	1,735	2,051	1,841	4,034
Total Liabilities & Equity	783	1,173	1,474	1,830	1,966	2,254	3,032	5,730

Cash Flow

Abridged

Understanding Cash Flow Statement

Cohance Lifesciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	2022 Mar 31	C 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	136.14	350.76	386.06	517.80	445.70	305.56	310.10	316.41
Working Capital - Increase/(Decrease)	-88.33	45.23	-12.17	-193.97	5.77	47.41	-32.14	20.76
Net CF from Operating Activities	47.81	395.99	373.89	323.84	451.47	352.97	277.96	337.17
Capital Expenditures - Net	56.79	99.28	110.81	75.19	285.84	51.79	155.71	199.36
Net CF from Investing Activities	-65.68	-421.89	-311.40	-136.21	-200.84	-364.19	-255.53	-257.53
Dividends Paid - Cash - Total	23.02	76.72	25.46	101.83	203.65	-	-	-
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	32.43
Debt - LT & ST - Issuance/(Retirement) - Total	51.78	103.41	-41.53	-48.45	-26.74	-6.35	13.75	-113.47
Net Cash Flow from Financing Activities	28.77	26.69	-67.01	-150.25	-230.39	-6.35	13.75	-131.04
Free Cash Flow to Equity	42.81	400.12	221.54	200.20	138.89	294.83	136.00	24.34
Free Operating CF net dividend	-31.99	219.85	237.59	146.83	-38.09	301.18	122.25	117.29
Free Operating CF	-8.97	296.57	263.04	248.65	165.56	301.18	122.25	117.29

Business Segment Analysis

FY End:

Mar 25

Cohance Lifesciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

pharmaceuticals (100.0%)₹ 155.71 Cr

Revenue / Sales

pharmaceuticals (100.0%)₹ 1,194.75 Cr

Assets

pharmaceuticals (100.0%)₹ 3,031.75 Cr

Operating Income

pharmaceuticals (100.0%)₹ 328.08 Cr

Regional Segment Analysis

FY End:

Mar 25

Cohance Lifesciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Europe (64.7%)₹ 758.59 CrUSA (21.7%)₹ 254.83 CrOthers (7.2%)₹ 83.88 CrIndia (6.4%)₹ 74.98 Cr

Historical Segment Analysis

Track how Cohance Lifesciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

pharmaceuticals	57	99	111	75	286	52	156

Frequently Asked Questions

What is the revenue of Cohance Lifesciences Ltd.?

The latest trailing twelve month revenue of Cohance Lifesciences Ltd. is ₹ 2,268.55 Cr, reflecting a 1-year growth of 89.88% and a 3-year CAGR of 19.21%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Cohance Lifesciences Ltd.?

The latest trailing twelve month net profit (PAT) of Cohance Lifesciences Ltd. is ₹ 179.23 Cr, with a 3-year earnings CAGR of -33.83%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Cohance Lifesciences Ltd.?

The trailing twelve month EBITDA of Cohance Lifesciences Ltd. is approximately ₹ 239.66 Cr (based on an operating margin of 10.56%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Cohance Lifesciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Cohance Lifesciences Ltd. is 4.68. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Cohance Lifesciences Ltd.?

The debt-to-equity ratio of Cohance Lifesciences Ltd. stands at 0.10. The interest coverage ratio is 6.44x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Cohance Lifesciences Ltd.?

The estimated book value per share of Cohance Lifesciences Ltd. is 102.24 (derived from a P/B ratio of 4.21 and market price of ₹ 430.80), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Cohance Lifesciences Ltd.?

The trailing twelve month operating cash flow of Cohance Lifesciences Ltd. is ₹ 337.17 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Cohance Lifesciences Ltd. report consolidated or standalone financials?

Cohance Lifesciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.